The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?

Autor:	Scott W. Canna, Fabrizio De Benedetti
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	IL-18 IL-18 blocker Refractory SJIA Biomarker driven trials IL-18ophathies Inflammasopathies Pediatrics RJ1-570 Diseases of the musculoskeletal system RC925-935
Zdroj:	Pediatric Rheumatology Online Journal, Vol 21, Iss S1, Pp 1-6 (2024)
Druh dokumentu:	article
ISSN:	1546-0096
DOI:	10.1186/s12969-023-00867-y
Popis:	Abstract Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that IL-18 is a uniquely specific biomarker for many of the subsets of SJIA most in need of new therapies, and it may define a class of diseases mediated by IL-18 excess. The consensus was that leveraging IL-18 remains our most promising “lead” for use in refractory SJIA as it may mechanistically explain the disease pathophysiology and lead to more targeted therapies.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/537d6e32416e48f980b48ea3ec208ea9 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.